Health Canada
Symbol of the Government of Canada
Consumer Product Safety

Incident Report

Subform I: General Information

1. Report Type.

New incident report

Incident Report Number: 2019-2390

2. Registrant Information.

Registrant Reference Number: M-072308-01-1

Registrant Name (Full Legal Name no abbreviations): Bayer CropScience Inc

Address: Suite 200, 160 Quarry Park Blvd S.E.

City: Calgary

Prov / State: Alberta

Country: Canada

Postal Code: T2C 3G3

3. Select the appropriate subform(s) for the incident.

Scientific Study

4. Date registrant was first informed of the incident.

5. Location of incident.

6. Date incident was first observed.

Product Description

7. a) Provide the active ingredient and, if available, the registration number and product name (include all tank mixes). If the product is not registered provide a submission number.


PMRA Registration No. 26232      PMRA Submission No.       EPA Registration No.


  • Active Ingredient(s)

7. b) Type of formulation.

Application Information

8. Product was applied?


9. Application Rate.

10. Site pesticide was applied to (select all that apply).

11. Provide any additional information regarding application (how it was applied, amount applied, the size of the area treated etc).

To be determined by Registrant

12. In your opinion, was the product used according to the label instructions?


Subform VII: Scientific Study

1. Study Reference

Title Flufenacet Diflufenican SC 600: Seedling Emergence and Seedling Growth Test on terrestrial non-target plants of 6 families (2 Monocotyledoneae, 4 Dicotv ledoneae) according to guideline: OECD Guideline for the Testing of Chemicals, Proposal for updated Guideline 208: "Terrestrial (Non-Target) Plant Test 208 A: Seedling Emergence and Seedling Growth Test", Draft Document, July 2000

Date 12-JUL-02

2. a) Is an extension needed to translate the document?


3. Type of incident identified in the study

New health or environmental hazard

4. Describe the incident identified in the study (e.g. study demonstrates an increased risk to non-Hodgkin's Lymphoma after exposure to pesticide X)

This mixed active substance formulation produced a lower endpoint than was previously reported from the solo flufenacet formulation.

5. a) Was the study discontinued before completion?


5. b) Provide the reason for discontinuation

6. If the study is ongoing, what is the expected completion date?

For Registrant use only

7. Provide supplemental information here

The tested formulation is neither registered nor representative of registered formulations in Canada. However, under the current adverse effects reporting requirements in Canada, we are required to submit any data on formulations showing an adverse effect regardless of whether or not the formulation is registered in Canada.